

IFW

CASE D0283A CIP

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Stephen C. D'Amico
Type or print name


Signature

9-20-05
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

FEDER ET AL.

APPLICATION NO: 10/635,977

FILED: AUGUST 7, 2003

FOR: POLYNUCLEOTIDES ENCODING A NOVEL TESTIS-SPECIFIC
TUBULIN TYROSINE-LIGASE-LIKE PROTEIN, BGS42

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants believe this paper is being filed before the mailing date of a first Office Action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-3880.


In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Copies of these references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
(609) 252-5289




Stephen C. D'Amico
Agent for Applicants
Reg. No. 46,652

Date: 9-20-05

FORM PTO-1449
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
D0283A CIP
APPLICATION NO.
10/635,977
APPLICANT
FEDER ET AL.
FILING DATE
AUGUST 7, 2003

Group

INFORMATION DISCLOSURE CITATION



U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM	WO00/55173	9/21/00	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AN	WO00/58473	10/5/00	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AO						<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	Altschul, et al., "Gapped Blast and PSI-BLAST: a new generation of protein database search programs", Nucleic Acids Res., Vol. 25 (17), pp. 3389-3402 (1997)
	AS	Bateman, et al., "The Pfam Protein Families Database", Nucleic Acids Res., Vol. 28(1), pp. 263-266 (2000)
	AT	Birney, et al., "Using GeneWise in the <i>Drosophila</i> Annotation Experiment", Genome Res., Vol. 10, pp. 547-548 (2000)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
D0283A CIP
APPLICATION NO.
10/635,977
APPLICANT
FEDER ET AL.
FILING DATE
AUGUST 7, 2003

Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

2AA	Bonaldo, et al., "Normalization and Subtraction: Two Approaches to Facilitate Gene Discovery", Genome Res., Vol. 6, pp. 791-806 (1996)
2AB	Carninci, et al., "[2] High-Efficiency Full-Length cDNA Cloning", Methods Enzy., Vol. 303, pp. 19-44 (1999)
2AC	Dunham, et al., "The DNA sequence of human chromosome 22", Nature, Vol. 402, pp. 489-495 (1999)
2AD	Elgar, et al., "Generation and Analysis of 25 Mb of Genomic DNA from the Pufferfish <i>Fugu rubripes</i> by Sequence Scanning", Genome Res., Vol. 9, pp. 960-971 (1999)
2AE	Ersfeld, et al., "Characterization of the Tubulin-Tyrosine Ligase", J. Cell Biol., Vol. 120(3), pp. 725-732 (1993)
2AF	Herman, et al., "Methylation-specific PCR: A novel PCR assay for methylation status of GpG islands", PNAS, Vol. 93, pp. 9821-9826 (1996)
2AG	Idriss, H.T., "Suppression of tubulin tyrosine ligase activity through reversible phosphorylation: a mechanism for inhibition of α -tubulin tyrosinylation", Medical Hypotheses, Vol. 56(2), pp. 129-133 (2001)
2AH	Mialhe, et al., "Tubulin Detyrosination Is a Frequent Occurrence in Breast Cancers of Poor Prognosis", Cancer Res., Vol. 61, pp. 5024-5027 (2001)
2AI	Needleman, et al., "A General Method Applicable to the Search for Similarities in the Amino Acid Sequence of Two Proteins", J. Mol. Biol., Vol. 48, pp. 443-453 (1970)
2AJ	Raybin, et al., "Enzyme Which Specifically Adds Tyrosine to the α Chain of Tubulin", Biochem., Vol. 16(10), pp. 2189-2194 (1977)
2AK	Takai, et al., "Comprehensive analysis of CpG islands in human chromosomes 21 and 22", PNAS, Vol. 99(6), pp. 3740-3745 (2002)
2AL	Trichet, et al., Characterization of the human tubulin tyrosine ligase-like 1 gene (TTLL1) mapping to 22q13.1", Gene, Vol. 257, pp. 109-117 (2000)
2AM	Wiemann, et al., "Toward a Catalog of Human Genes and Proteins: Sequencing and Analysis of 500 Novel Complete Protein Coding Human cDNAs", Genome Res., Vol. 11, pp. 422-435 (2001)
2AN	NCBI Entrez Accession No. A45443 (gi:423218), Ersfeld, et al., June 3, 2002

EXAMINER**DATE CONSIDERED**

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE**INFORMATION DISCLOSURE CITATION***(Use several sheets if necessary)*ATTY. DOCKET NO.
D0283A CIP
APPLICATION NO.
10/635,977
APPLICANT
FEDER ET AL.
FILING DATE
AUGUST 7, 2003

Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

3AA	NCBI Entrez Accession No. AAF23353 (gi:6683745), Yu, et al., January 9, 2000
3AB	NCBI Entrez Accession No. AA061487 (gi:1555346), Marra, et al., February 3, 1997
3AC	NCBI Entrez Accession No. AA144756 (gi:1714179), Marra, et al., February 11, 1997
3AD	NCBI Entrez Accession No. AF078842 (gi:6683744), Yu, et al., January 9, 2000
3AE	NCBI Entrez Accession No. AI026623 (gi:3246111), NCI-CGAP, August 27, 1998
3AF	NCBI Entrez Accession No. AL022327 (gi:5304851), Cobley, V., May 18, 2005
3AG	NCBI Entrez Accession No. AL026623 (gi:3263966), Elgar, et al., February 25, 2004
3AH	NCBI Entrez Accession No. AL096725 (gi:5419858), Wambutt, et al., February 18, 2000
3AI	NCBI Entrez Accession No. BB004438 (gi:8093886), Konno, et al., June 22, 2000
3AJ	NCBI Entrez Accession No. BE102364 (gi:8494463), Bonaldo, et al., June 13, 2000
3AK	NCBI Entrez Accession No. BM808516 (gi:19125339), NIH-MGC, March 5, 2002
3AL	NCBI Entrez Accession No. BM808637 (gi:19125460), NIH-MGC., March 5, 2002
3AM	NCBI Entrez Accession No. BU937372 (gi:24126191), NIH-MGC, October 18, 2002
3AN	NCBI Entrez Accession No. CAB46375 (gi:5419859), Wambutt, et al., February 18, 2000

EXAMINER**DATE CONSIDERED**

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449
(REV. 7-85)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
D0283A CIP
APPLICATION NO.
10/635,977
APPLICANT
FEDER ET AL.
FILING DATE
AUGUST 7, 2003

Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

4AA	NCBI Entrez Accession No. CAI42686 (gi:57208207), Cobley, V., May 18, 2005
4AB	NCBI Entrez Accession No. CK604006 (gi:41117345), NIH-MGC, January 22, 2004
4AC	NCBI Entrez Accession No. CK653583 (gi:41389106), NIH-MGC, January 29, 2004
4AD	NCBI Entrez Accession No. CR745100 (gi:51667573), Ebert, et al., December 21, 2004
4AE	NCBI Entrez Accession No. CX205198 (gi:56860370), Williams, C., December 29, 2004
4AF	NCBI Entrez Accession No. DN831611 (gi:62640254), Stevens, et al., April 27, 2005
4AG	NCBI Entrez Accession No. DN831612 (gi:62640255), Stevens, et al., April 27, 2005
4AH	NCBI Entrez Accession No. DN831950 (gi:62640634), Stevens, et al., April 27, 2005
4AI	NCBI Entrez Accession No. DN831951 (gi:62640635), Stevens, et al., April 27, 2005
4AJ	NCBI Entrez Accession No. DR008133 (gi:66272229), Stevens, et al., May 18, 2005
4AK	NCBI Entrez Accession No. DR008134 (gi:66272231), Stevens, et al., May 18, 2005
4AL	NCBI Entrez Accession No. Q9Y4R7 (gi:20455371), Yu, et al., September 13, 2005
4AM	NCBI Entrez Accession No. T12515 (gi:597202), Liew, et al., November 28, 1994
4AN	NCBI Entrez Accession No. XP_104657 (gi:37564887), NCBI Annotation Process, February 19, 2004

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449
(REV. 7-85)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
D0283A CIP
APPLICATION NO.
10/635,977
APPLICANT
FEDER ET AL.
FILING DATE
AUGUST 7, 2003

Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

5AA	NCBI Entrez Accession No. XP_104657 (gi:51476104), NCBI Annotation Process, August 20, 2004
5AB	NCBI Entrez Accession No. XP_515212 (gi:55661552), NCBI Annotation Process,, November 9, 2004
5AC	Baylin, et al., "Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer", Human Molecular Genetics", Vol. 10(7), pp. 687-692 (2001)
AD	
AE	
AF	
AG	
AH	
AI	
AJ	
AK	
AL	
AM	
AN	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.